ArcherDX

ArcherDX

Elevating molecular pathology for genetic insights with advanced sequencing and innovative bioinformatics tools.

Founded 2013 201-500 employees Series C Total: $150.00M Biopharma, Biotechnology +1

ArcherDX, Elevating molecular pathology for genetic insights with advanced sequencing and innovative bioinformatics tools. Founded in 2013, the company is revolutionizing molecular pathology through its comprehensive technology platform. Utilizing its unique Anchored Multiplexed PCR (AMP™) chemistry in a user-friendly, lyophilized format combined with advanced bioinformatics software, the Archer® platform significantly improves the identification and discovery of genetic mutations, particularly in oncology-focused research products. The company recently secured a significant $55.00M Series C investment on 17 December 2019 from a consortium of prominent investors, including Boulder Ventures, Longwood Fund, Redmile Group, Sands Capital Ventures, ArrowMark Partners, Driehaus Capital Management, PBM Capital, Perceptive Advisors, and Soleus Capital. Currently, ArcherDX is not specifically headquartered, and is seeking regulatory approval for several companion diagnostic assays. With its innovative approach and strong investor backing, ArcherDX is well-positioned to make substantial strides in the biopharma and biotechnology industries, enhancing the detection of genetic mutations and potentially reshaping molecular pathology.

Funding Stage	Amount	Investors	Lead Investors	Date
Series C	$55.00M	9	Boulder Ventures, Longwood Fund +7	17 Dec 2019
Series B	$60.00M	1	The Peierls Foundation	15 May 2019
Series A	$35.00M	-		20 Mar 2018

Funding Stage

Amount

Investors

Lead Investors

Date

Series C

$55.00M

Boulder Ventures, Longwood Fund +7

17 Dec 2019

Series B

$60.00M

The Peierls Foundation

15 May 2019

Series A

$35.00M

20 Mar 2018

FAQ About ArcherDX

Elevating molecular pathology for genetic insights with advanced sequencing and innovative bioinformatics tools.

ArcherDX was founded in 2013.

ArcherDX operates in Biopharma, Biotechnology and Life Sciences. Its work centres on molecular pathology, genetic insights, next-generation sequencing and bioinformatics tools.

ArcherDX has approximately 201-500 employees.

ArcherDX has completed 3 funding rounds, raising a total of $150.00M. The latest funding stage is Series C.

Top alternatives and competitors to ArcherDX include Annoroad Genomics, Polgen Biyoteknoloji, LCM Genect, BMR Genomics, SciGenom Labs. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

ArcherDX and Annoroad Genomics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About ArcherDX

Funding Rounds & Investors (3)

ArcherDX Alternatives & Competitors

FAQ About ArcherDX